Herold Advisors Inc. Acquires 240 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Herold Advisors Inc. grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 16.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,729 shares of the medical research company’s stock after purchasing an additional 240 shares during the quarter. Herold Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $918,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Meridian Wealth Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 2.2% in the third quarter. Meridian Wealth Management LLC now owns 2,147 shares of the medical research company’s stock worth $1,087,000 after buying an additional 47 shares in the last quarter. Strategic Blueprint LLC lifted its holdings in shares of Thermo Fisher Scientific by 7.8% in the third quarter. Strategic Blueprint LLC now owns 1,124 shares of the medical research company’s stock worth $569,000 after buying an additional 81 shares in the last quarter. Coastline Trust Co lifted its holdings in shares of Thermo Fisher Scientific by 0.7% in the third quarter. Coastline Trust Co now owns 12,364 shares of the medical research company’s stock worth $6,258,000 after buying an additional 88 shares in the last quarter. Coronation Fund Managers Ltd. raised its stake in Thermo Fisher Scientific by 31.4% in the third quarter. Coronation Fund Managers Ltd. now owns 96,509 shares of the medical research company’s stock valued at $48,850,000 after purchasing an additional 23,086 shares in the last quarter. Finally, DeDora Capital Inc. raised its stake in Thermo Fisher Scientific by 9.8% in the third quarter. DeDora Capital Inc. now owns 1,706 shares of the medical research company’s stock valued at $864,000 after purchasing an additional 152 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.3 %

Shares of Thermo Fisher Scientific stock opened at $573.60 on Friday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.39 and a current ratio of 1.70. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $603.82. The stock has a market capitalization of $218.95 billion, a price-to-earnings ratio of 36.79, a P/E/G ratio of 2.41 and a beta of 0.80. The company’s 50 day moving average price is $573.60 and its 200-day moving average price is $529.90.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.70 by $0.41. The firm had revenue of $10.35 billion for the quarter, compared to analysts’ expectations of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 21.54 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were issued a $0.39 dividend. The ex-dividend date was Thursday, March 14th. This represents a $1.56 annualized dividend and a yield of 0.27%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s payout ratio is 10.01%.

Analysts Set New Price Targets

A number of brokerages recently weighed in on TMO. Royal Bank of Canada raised their target price on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Barclays raised their target price on shares of Thermo Fisher Scientific from $590.00 to $615.00 and gave the company an “equal weight” rating in a research note on Thursday. HSBC raised their target price on shares of Thermo Fisher Scientific from $630.00 to $660.00 and gave the company a “buy” rating in a research note on Wednesday, April 17th. The Goldman Sachs Group lifted their price target on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research note on Thursday. Five equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $606.76.

Insider Activity at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the sale, the senior vice president now owns 12,901 shares in the company, valued at $7,250,362. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the transaction, the chief executive officer now owns 49,155 shares of the company’s stock, valued at $27,311,992.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the transaction, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The disclosure for this sale can be found here. Insiders have sold a total of 50,277 shares of company stock worth $28,513,384 over the last quarter. Corporate insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.